Medium-term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer

BJU International

Volumn 115, Issue 6, 2015, Pages 884-891

  Thompson, James E ^a,b,c   Hayen, Andrew ^d   Landau, Adam ^e   Haynes, Anne Maree ^b   Kalapara, Arveen ^e   Ischia, Joseph ^e   Matthews, Jayne ^a   Frydenberg, Mark ^e   Stricker, Phillip D ^a,b,c  

^a ST VINCENT'S CLINIC   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

active surveillance; disease management; needle biopsy; predictive value of diagnostic tests; prostate cancer

Indexed keywords

ADULT; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FAMILY HISTORY; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADICAL TREATMENT FREE SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SATURATION BIOPSY; SURVIVAL RATE; SURVIVAL TIME; TIME TO TREATMENT; TRANSPERINEAL BIOPSY; TRANSRECTAL BIOPSY; TUMOR VOLUME; BIOPSY; COHORT ANALYSIS; COMPARATIVE STUDY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROSTATE TUMOR; TREATMENT OUTCOME;

BIOPSY; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84930014727     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12858     Document Type: Article

References (31)

1. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079-1092
2. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29
3. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
4. Heijnsdijk EA, Der Kinderen A, Wever EM, Draisma G, Roobol MJ, De Koning HJ,. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer 2009; 101: 1833-1838
5. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP,. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71 (Suppl.): 933-938
6. Epstein JI, Walsh PC, Carmichael M, Brendler CB,. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-374
7. Wolters T, Roobol MJ, Van Leeuwen PJ, et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011; 185: 121-125
8. Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI,. Do adenocarcinomas of the prostate with Gleason score (GS)
9. Selvadurai ED, Singhera M, Thomas K, et al. Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol 2013; 64: 981-987
10. Cooperberg MR, Cowan JE, Hilton JF, et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 2011; 29: 228-234
11. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A,. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-131
12. Dall'Era MA, Albertsen PC, Bangma C, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012; 62: 976-983
13. Russo GI, Cimino S, Castelli T, et al. Percentage of cancer involvement in positive cores can predict unfavorable disease in men with low-risk prostate cancer but eligible for the prostate cancer international: active surveillance criteria. Urol Oncol 2014; 32: 291-296
14. Epstein JI, Feng Z, Trock BJ, Pierorazio PM,. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 2012; 61: 1019-1024
15. Bul M, Zhu X, Rannikko A, et al. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol 2012; 62: 195-200
16. Linder BJ, Frank I, Umbreit EC, et al. Standard and saturation transrectal prostate biopsy techniques are equally accurate among prostate cancer active surveillance candidates. Int J Urol 2013; 20: 860-864
17. Bjurlin MA, Carter HB, Schellhammer P, et al. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol 2013; 189: 2039-2046
18. Hossack T, Patel MI, Huo A, et al. Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy. J Urol 2012; 188: 781-785
19. Ayres BE, Montgomery BS, Barber NJ, et al. The role of transperineal template prostate biopsies in restaging men with prostate cancer managed by active surveillance. BJU Int 2012; 109: 1170-1176
20. Adamy A, Yee DS, Matsushita K, et al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol 2011; 185: 477-482
21. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29: 2185-2190
22. Bul M, Zhu X, Valdagni R, et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013; 63: 597-603
23. Klotz L,. Active surveillance: the Canadian experience. Curr Opin Urol 2012; 22: 222-230
24. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203-213
25. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364: 1708-1717
26. Cooperberg MR, Carroll PR, Klotz L,. Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011; 29: 3669-3676
27. Thompson J, Lawrentschuk N, Frydenberg M, Thompson L, Stricker P, USANZ. The role of magnetic resonance imaging in the diagnosis and management of prostate cancer. BJU Int 2013; 112 (Suppl. 2): 6-20
28. Moore CM, Ridout A, Emberton M,. The role of MRI in active surveillance of prostate cancer. Curr Opin Urol 2013; 23: 261-267
29. Hirama H, Sugimoto M, Ito K, Shiraishi T, Kakehi Y,. The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J Cancer Res Clin Oncol 2014; 140: 257-263
30. Van Den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker CC,. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. Eur Urol 2014; 65: 1023-1031
31. Lawrentschuk N, Haider MA, Daljeet N, et al. 'Prostatic evasive anterior tumours': the role of magnetic resonance imaging. BJU Int 2010; 105: 1231-1236